3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Vascular Reactivity Profile of Novel KCa3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="P1">Opening of intermediate-conductance calcium-activated potassium channels (K <sub>Ca</sub>3.1) produces membrane hyperpolarization in the vascular endothelium. Here, we studied the ability of two new K <sub>Ca</sub>3.1-selective positive-gating modulators, SKA-111 and SKA-121, to (1) evoke porcine endothelial cell K <sub>Ca</sub>3.1 membrane hyperpolarization, (2) induce endothelium-dependent and, particularly, endothelium-derived hyperpolarization (EDH)-type relaxation in porcine coronary arteries (PCA) and (3) influence coronary artery tone in isolated rat hearts. In whole-cell patch-clamp experiments on endothelial cells of PCA (PCAEC), K <sub>Ca</sub> currents evoked by bradykinin (BK) were potentiated ≈7-fold by either SKA-111 or SKA-121 (both at 1 μM) and were blocked by a K <sub>Ca</sub>3.1 blocker, TRAM-34. In membrane potential measurements, SKA-111 and SKA-121 augmented bradykinin-induced hyperpolarization. Isometric tension measurements in large- and small-calibre PCA showed that SKA-111 and SKA-121 potentiated endothelium-dependent relaxation with intact NO synthesis and EDH-type relaxation to BK by ≈2-fold. Potentiation of the BK response was prevented by K <sub>Ca</sub>3.1 inhibition. In Langendorff-perfused rat hearts, SKA-111 potentiated coronary vasodilation elicited by BK. In conclusion, our data show that positive-gating modulation of K <sub>Ca</sub>3.1 channels improves BK-induced membrane hyperpolarization and endothelium-dependent relaxation in small and large PCA as well as in the coronary circulation of rats. Positive-gating modulators of K <sub>Ca</sub>3.1 could be therapeutically useful to improve coronary blood flow and counteract impaired coronary endothelial dysfunction in cardiovascular disease. </p>

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          A human intermediate conductance calcium-activated potassium channel.

          An intermediate conductance calcium-activated potassium channel, hIK1, was cloned from human pancreas. The predicted amino acid sequence is related to, but distinct from, the small conductance calcium-activated potassium channel subfamily, which is approximately 50% conserved. hIK1 mRNA was detected in peripheral tissues but not in brain. Expression of hIK1 in Xenopus oocytes gave rise to inwardly rectifying potassium currents, which were activated by submicromolar concentrations of intracellular calcium (K0.5 = 0.3 microM). Although the K0.5 for calcium was similar to that of small conductance calcium-activated potassium channels, the slope factor derived from the Hill equation was significantly reduced (1.7 vs. 3. 5). Single-channel current amplitudes reflected the macroscopic inward rectification and revealed a conductance level of 39 pS in the inward direction. hIK1 currents were reversibly blocked by charybdotoxin (Ki = 2.5 nM) and clotrimazole (Ki = 24.8 nM) but were minimally affected by apamin (100 nM), iberiotoxin (50 nM), or ketoconazole (10 microM). These biophysical and pharmacological properties are consistent with native intermediate conductance calcium-activated potassium channels, including the erythrocyte Gardos channel.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              MitoBK(Ca) is encoded by the Kcnma1 gene, and a splicing sequence defines its mitochondrial location.

              The large-conductance Ca(2+)- and voltage-activated K(+) channel (BK(Ca), MaxiK), which is encoded by the Kcnma1 gene, is generally expressed at the plasma membrane of excitable and nonexcitable cells. However, in adult cardiomyocytes, a BK(Ca)-like channel activity has been reported in the mitochondria but not at the plasma membrane. The putative opening of this channel with the BK(Ca) agonist, NS1619, protects the heart from ischemic insult. However, the molecular origin of mitochondrial BK(Ca) (mitoBK(Ca)) is unknown because its linkage to Kcnma1 has been questioned on biochemical and molecular grounds. Here, we unequivocally demonstrate that the molecular correlate of mitoBK(Ca) is the Kcnma1 gene, which produces a protein that migrates at ∼140 kDa and arranges in clusters of ∼50 nm in purified mitochondria. Physiological experiments further support the origin of mitoBK(Ca) as a Kcnma1 product because NS1619-mediated cardioprotection was absent in Kcnma1 knockout mice. Finally, BKCa transcript analysis and expression in adult cardiomyocytes led to the discovery of a 50-aa C-terminal splice insert as essential for the mitochondrial targeting of mitoBK(Ca).
                Bookmark

                Author and article information

                Journal
                Basic & Clinical Pharmacology & Toxicology
                Basic Clin Pharmacol Toxicol
                Wiley
                17427835
                August 2016
                August 2016
                February 29 2016
                : 119
                : 2
                : 184-192
                Affiliations
                [1 ]Aragon Institute of Health Sciences & IIS; Zaragoza Spain
                [2 ]Department of Pharmacy; Faculty of Health Sciences; Universidad San Jorge; Villanueva de Gállego Spain
                [3 ]Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology; Aarhus University; Aarhus Denmark
                [4 ]Department of Physiology; Faculty of Medicine; Universidad Autónoma de Madrid; Madrid Spain
                [5 ]Department of Pharmacology; University of California; Davis CA USA
                [6 ]Laboratori de Fisiologia Molecular i Canalopaties; Departament de Ciències Experimentals i de la Salut; Universitat Pompeu Fabra; Barcelona Spain
                [7 ]Department of Pharmacology and Physiology; Veterinary Faculty; University of Zaragoza; Zaragoza Spain
                [8 ]Departamento de Catálisis y Procesos Catalíticos; Instituto de Síntesis Química y Catálisis Homogénea (ISQCH); CSIC - Universidad de Zaragoza; Zaragoza Spain
                [9 ]Department of Physiology; Faculty of Pharmacy; Universidad Complutense de Madrid; Madrid Spain
                [10 ]Aragon Agency for Research and Development (ARAID); Zaragoza Spain
                Article
                10.1111/bcpt.12560
                5720859
                26821335
                8718316a-3fc1-4398-a7af-b9eace177e94
                © 2016

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article